From Follower to Leader: Ruijin Hospital Achieves 21.2% Five-Year Survival in Pancreatic Cancer
During China’s National Cancer Prevention Week, the international journal ESMO Gastrointestinal Oncology published the Pancreatic Cancer Systemic Therapy Asia-Pacific Expert Consensus — and at its center was one Chinese institution: Ruijin Hospital.
Prof. Shen Baiyong (沈柏用), Vice President of Ruijin Hospital and Director of its Pancreatic Disease Center, was the only Chinese expert among the consensus’s core authors. His team’s clinical data — accumulated over 30,000 cases — provided the evidence backbone for treatment recommendations that will shape pancreatic cancer care across Asia.
The Problem: “King of Cancers”
Pancreatic cancer earns its grim title for three reasons:
- Late detection: Over 80% of patients are diagnosed at advanced stages. Five-year survival is under 8% globally.
- High recurrence: Even after curative surgery, 70% of patients face recurrence.
- Treatment scarcity: Compared to breast cancer or lung cancer, pancreatic cancer has far fewer targeted therapies and immunotherapy options.
Ruijin’s approach attacks all three problems simultaneously.
Early Detection: 12-Dimensional Risk Model
Prof. Shen’s team developed a multi-dimensional risk prediction model using epidemiological and clinical data, screening for 12 high-risk indicators. The system has already:
- Collected nearly 40,000 valid data points
- Identified 1,000+ high-risk individuals for dynamic monitoring
- Developed a next-generation screening kit that moves the cancer warning window forward by 3–6 months compared to traditional CA19-9 testing
They also built the “Pancreatic Health” app — a mobile platform for population-level screening, now being piloted in Shanghai’s Huangpu District.
Precision Treatment: The “Gene ID Card”
“Before we treat, we need to know who responds to what,” Prof. Shen explains. His team uses molecular profiling — what he calls the tumor’s “gene ID card” (基因身份证) — to match patients with the most effective therapy:
- BRCA mutations → highly sensitive to platinum-based chemo + PARP inhibitors
- MSI-H tumors → potential response to immunotherapy
- KRAS mutations → eligibility for mRNA vaccine trials and KRAS inhibitors
This molecular-guided approach is now standard practice at Ruijin’s pancreatic center.
The Numbers That Changed the Game
| Metric | Ruijin | Global Average |
|---|---|---|
| Cumulative cases treated | 30,000+ | — |
| 5-year overall survival | 21.2% | 9–12% |
| 5-year survival (Stage I) | 35.3% | — |
| Da Vinci robotic pancreatic surgeries | 4,000+ (2,000+ malignant) | — |
| Global ranking (robotic volume) | #2 worldwide, #1 in China | — |
| Complex pancreatic surgeries/year | 2,000+ | — |
These aren’t aspirational targets. They’re published, auditable results that have earned recognition from Germany’s Heidelberg University, the American Pancreas Society, and the French Academy of Medicine — all of whom have cited Ruijin as an emerging “new center” in global pancreatic cancer care.
mRNA Vaccine: World’s First for KRAS G12V
In June 2024, Cell Research (IF 28.1) published Ruijin’s landmark study: the world’s first mRNA tumor vaccine targeting KRAS G12V in solid tumors, combined with pembrolizumab (PD-1 inhibitor).
The first treated patient — an 86-year-old woman with locally advanced pancreatic cancer — achieved:
- 31% tumor reduction after 3 treatment cycles
- 17 months disease-free
- 27 months overall survival
The vaccine is now in Phase I clinical trials at Ruijin, actively enrolling patients. This is not a laboratory concept — it is a treatment being administered to real patients.
International Training: Spreading the Technique
Starting in 2025, Ruijin’s pancreatic center hosts monthly international training workshops for robotic pancreatic surgery, open to surgeons from China and abroad. The goal: standardize robotic pancreatic surgery techniques globally and make the expertise accessible beyond Ruijin’s walls.
Why This Matters for International Patients
Ruijin’s rise from a national leader to a global benchmark means:
- Access to cutting-edge treatment: mRNA vaccines, precision medicine, robotic surgery — all under one roof
- Data-driven confidence: 30,000+ cases provide the statistical power that small centers cannot
- International language support: English-speaking coordinators, video consultations, discharge summaries in English
- Integrated care: Surgery + medical oncology + pathology + clinical trials — all coordinated within a single MDT team
Based on reporting by 医师报 (Chinese Medical News). Last updated: May 2026. This article does not constitute medical advice.